|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Igm Biosciences, Inc. (IGMS) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
24,220,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile IGM Biosciences is a clinical-stage biotechnology company engaging in the development of Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Co.'s primary product candidate, IGM-2323, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. Co.'s second product candidate, IGM-8444, is an IgM antibody targeting Death Receptor 5 proteins. Co.'s pipeline also includes IGM-7354, a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell targeting CD38 and CD3 proteins and IGM-2537, a bispecific T cell targeting CD123, and CD3 proteins.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
395,317 |
928,010 |
1,130,933 |
1,227,818 |
| Total Buy Value |
$3,425,569 |
$6,857,033 |
$8,606,797 |
$10,246,311 |
| Total People Bought |
1 |
1 |
5 |
6 |
| Total Buy Transactions |
3 |
6 |
11 |
20 |
| Total Shares Sold |
28,125 |
64,791 |
154,362 |
286,636 |
| Total Sell Value |
$281,621 |
$492,429 |
$1,355,835 |
$4,051,715 |
| Total People Sold |
6 |
7 |
8 |
8 |
| Total Sell Transactions |
12 |
21 |
30 |
62 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tahir Misbah |
Chief Financial Officer |
• – – |
2022-11-23 |
4 |
S |
$21.38 |
$18,918 |
D/D |
(877) |
33,174 |
|
- |
|
| Takimoto Chris H |
Chief Medical Officer |
• – – |
2022-11-23 |
4 |
S |
$21.38 |
$18,918 |
D/D |
(877) |
35,987 |
|
- |
|
| Tahir Misbah |
Chief Financial Officer |
• – – |
2022-11-15 |
4 |
A |
$12.84 |
$4,533 |
D/D |
353 |
34,051 |
|
- |
|
| Behrens M Kathleen |
Director |
– • – |
2022-11-08 |
4 |
B |
$17.14 |
$1,028,550 |
I/I |
60,000 |
218,200 |
2.1 |
- |
|
| Loberg Michael D |
Director |
– • – |
2022-10-14 |
4 |
GA |
$0.00 |
$0 |
I/I |
533 |
35,838 |
|
- |
|
| Loberg Michael D |
Director |
– • – |
2022-10-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
533 |
0 |
|
- |
|
| Keyt Bruce |
Chief Scientific Officer |
• – – |
2022-10-04 |
4 |
AS |
$22.84 |
$570,980 |
D/D |
(25,000) |
39,489 |
|
- |
|
| Keyt Bruce |
Chief Scientific Officer |
• – – |
2022-10-04 |
4 |
OE |
$0.93 |
$23,250 |
D/D |
25,000 |
64,489 |
|
- |
|
| Green Jeremy |
10% Owner |
– – • |
2022-10-03 |
4 |
A |
$22.49 |
$4,971,909 |
I/I |
221,072 |
3,336,277 |
|
- |
|
| Green Jeremy |
10% Owner |
– – • |
2022-10-03 |
4 |
D |
$22.49 |
$4,971,909 |
I/I |
(221,072) |
3,336,277 |
|
- |
|
| Lee Michael Stewart |
Director |
– • – |
2022-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
230 |
1,922 |
|
- |
|
| Green Jeremy |
10% Owner |
– – • |
2022-09-30 |
4 |
A |
$0.00 |
$0 |
I/I |
230 |
3,336,277 |
|
- |
|
| Topsoe Jakob Haldor |
Director |
– • • |
2022-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
230 |
73,922 |
|
- |
|
| Loberg Michael D |
Director |
– • – |
2022-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
533 |
533 |
|
- |
|
| Topsoe Christina Teng |
Director |
– • • |
2022-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
346 |
37,621 |
|
- |
|
| Behrens M Kathleen |
Director |
– • – |
2022-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
374 |
3,394 |
|
- |
|
| Loberg Michael D |
Director |
– • – |
2022-09-29 |
4 |
B |
$19.62 |
$114,213 |
I/I |
5,821 |
35,305 |
2.1 |
- |
|
| Loberg Michael D |
Director |
– • – |
2022-09-28 |
4 |
B |
$20.97 |
$129,403 |
I/I |
6,172 |
29,484 |
2.1 |
- |
|
| Loberg Michael D |
Director |
– • – |
2022-09-27 |
4 |
B |
$19.99 |
$10,137 |
I/I |
507 |
23,312 |
2.1 |
- |
|
| Keyt Bruce |
Chief Scientific Officer |
• – – |
2022-09-08 |
4 |
AS |
$19.57 |
$197,827 |
D/D |
(10,000) |
39,489 |
|
- |
|
| Keyt Bruce |
Chief Scientific Officer |
• – – |
2022-09-08 |
4 |
OE |
$0.93 |
$9,300 |
D/D |
10,000 |
49,489 |
|
- |
|
| Keyt Bruce |
Chief Scientific Officer |
• – – |
2022-09-07 |
4 |
AS |
$19.04 |
$190,392 |
D/D |
(10,000) |
39,489 |
|
- |
|
| Keyt Bruce |
Chief Scientific Officer |
• – – |
2022-09-07 |
4 |
OE |
$0.93 |
$9,300 |
D/D |
10,000 |
49,489 |
|
- |
|
| Keyt Bruce |
Chief Scientific Officer |
• – – |
2022-09-06 |
4 |
AS |
$19.06 |
$95,321 |
D/D |
(5,000) |
39,489 |
|
- |
|
| Keyt Bruce |
Chief Scientific Officer |
• – – |
2022-09-06 |
4 |
OE |
$0.93 |
$4,650 |
D/D |
5,000 |
44,489 |
|
- |
|
422 Records found
|
|
Page 6 of 17 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
